containing 100 mM TES (N-tris[hydroxymethyl]methyl-2-aminoethanesulfonic acid) at pH 7.6 and 1 mg of NTG (N-methyl-N'-nitro-N-nitrosoguanidine) per ml. After 35 min of incubation, cells were harvested, washed three times, and inoculated onto GER plates. After growing out for 4 days at 28°C, mycelia were harvested, resuspended in 10% sucrose, and fragmented by sonication (1) . Fragmented mycelia were diluted and inoculated onto GER plates to obtain discrete colonies. Alternatively, cells were grown out on yeast dextrose slants. After inoculation at 30°C for 4 weeks, a spore preparation was made as described previously (6) . Spores were diluted and inoculated on GER plates to obtain colonies.
Mutants defective in calicheamicin production were identified by using the biological induction assay (BIA), in which f-galactosidase production is induced in Escherichia coli BR513 in response to DNA-damaging agents (4). Colonies were grown in 24-well plates (Corning) containing 1.5 ml of production medium (3) and one glass bead per well. After 1 week, 10 pW of each fermentation was applied to a BIA plate to identify calicheamicin nonproducers. Nonproducing cultures were discarded if they carried mutations that caused * Corresponding author. slow growth, auxotrophy, or the inability to make the orange pigment normally produced by the wild type during stationary phase, at the time calicheamicin appears (3) . Fifteen nonproducing mutants, obtained from 480 survivors of NTG treatment, were studied further.
Cosynthesis studies with blocked mutants. Two mutants blocked in the same biosynthetic pathway may be able to cosynthesize the final product by a cross-feeding mechanism (2, 11, 12) . We reasoned that if two mutants cosynthesize calicheamicin, then they must contain lesions in distinct genes. (However, if two mutants fail to cosynthesize, no conclusion can be drawn, since an unstable or nondiffusable intermediate may be responsible for the negative result.) Our 15 nonproducing mutants assorted into 10 distinct cosynthesis classes (Table 1) . One additional mutant exhibited the same cosynthesis pattern as strain DR210, and four additional mutants were similar to strain DR1014.
Conversion of pseudoaglycon to calicheamicin by blocked mutants. Pseudoaglycon is a product of methanolysis of calicheamicin which lacks two sugar substituents (8) (Fig. 1) . To obtain additional evidence that mutants were blocked specifically in the calicheamicin biosynthetic pathway, three mutants were tested for the ability to convert pseudoaglycon to a final product. Stationary-phase cultures of strains DR43, DR46, and DR1316 were supplemented with pseudoaglycon, and then extracts were analyzed by thin-layer chromatography to identify calicheamicins. Fermentations were mixed with solvents (8/5, vol/vol, acetone-ethyl acetate), and the organic phase was saved. The solvent was evaporated, and the extract was resuspended in ethyl acetate and applied to a thin-layer plate as described previously (9), which was then applied to a BIA plate. Figure 2 indicates that pseudoaglycon, which exhibits a weak BIA activity, was converted to calicheamicins by all three mutant strains tested. Thus, these mutants are unable to synthesize a chemical bond or substituent found within pseudoaglycon.
Intermediates produced by blocked mutant strains. In order to identify calicheamicin biosynthetic intermediates, it was first necessary to determine which strain of a cosynthesizing pair secreted the intermediate and which strain converted it to calicheamicin. Cell extracts were prepared by mixing a bacterial culture with an equal volume of acetone, drying down the supernatant following centrifugation, and resuspending the dried material in water. The converting strain of a pair was able to produce calicheamicin when provided with an extract of the secreting strain.
Our results showed that strain DR43 could convert extracted material from strains DR46, DR1712, DR1316, DR118, DR210, and DR123; the intermediates produced by strains DR46, DR1712, and DR1316 were water soluble and were found in culture supernatants, whereas the nature of It is interesting that strains DR43 and DR46 coproduced the beta form, but not the gamma form, of calicheamicin, whereas the wild-type strain produced the beta and gamma forms as major products (Fig. 3) Mutants with an altered profile of calicheamicin forms. The predominant calicheamicin forms of wild-type cultures were beta and gamma, which differ in substituents on the amino sugar (Fig. 1) . By screening survivors of NTG treatment by thin-layer chromatography, we detected mutants that produced calicheamicins with altered profiles. Figure 4 shows profiles of two mutant strains. Strain DR414 produced only the delta form, and strain DR1122 produced the delta and gamma forms. The existence of such mutants suggests that the conversion of delta, beta, and gamma forms may involve the sequential addition of methyl groups onto the nitrogen of amino sugar E (Fig. 1) . We do not as yet know, however, whether each mutant strain contains a genetic defect resulting in the loss of a single enzyme function.
Further analysis of these mutants defective in calicheamicin biosynthesis will provide useful tools for determining the biosynthetic pathway of this unusual family of compounds. Both the identification of calicheamicin intermediates and the complementation of mutations by cloned DNA fragments will provide this information. 
